{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:23:47Z","timestamp":1792103027419,"version":"4.4.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biol Toxicol"],"DOI":"10.1007\/s10565-024-09984-0","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T22:02:26Z","timestamp":1737151346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The important role of the histone acetyltransferases p300\/CBP in cancer and the promising anticancer effects of p300\/CBP inhibitors"],"prefix":"10.1007","volume":"41","author":[{"given":"Xin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoshan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"9984_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41417-022-00524-8","volume":"30","author":"MSZ Ansari","year":"2023","unstructured":"Ansari MSZ, Stagni V, Iuzzolino A, Rotili D, Mai A, Del Bufalo D, Lavia P, Degrassi F, Trisciuoglio D. Pharmacological targeting of CBP\/p300 drives a redox\/autophagy axis leading to senescence-induced growth arrest in non-small cell lung cancer cells. Cancer Gene Ther. 2023;30:124\u201336. https:\/\/doi.org\/10.1038\/s41417-022-00524-8.","journal-title":"Cancer Gene Ther"},{"key":"9984_CR2","doi-asserted-by":"crossref","unstructured":"Armstrong AJ, Gordon MS, Reimers MA, Hussain A, Patel VG, Lam ET, Sedkov A, Potter V, Shore N. Initial findings from an ongoing first-in-human phase 1 study of the CBP\/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer [abstract]. In: Proceedings of the AACR-NCI-EORTC virtual international conference on molecular targets and cancer therapeutics; 2021 Oct 7\u201310. Philadelphia (PA): AACR. Mol Cancer Ther. 2021;20(12 Suppl):Abstract nr P202.\u00a0https:\/\/aacrjournals.org\/mct\/article\/20\/12_Supplement\/P202\/675930\/Abstract-P202-Initial-findings-from-an-ongoing.","DOI":"10.1158\/1535-7163.TARG-21-P202"},{"key":"9984_CR3","doi-asserted-by":"publisher","first-page":"8361","DOI":"10.1038\/s41467-023-43780-4","volume":"14","author":"Y Asante","year":"2023","unstructured":"Asante Y, Benischke K, Osman I, Ngo QA, Wurth J, Laubscher D, Kim H, Udhayakumar B, Khan MIH, Chin DH, Porch J, Chakraborty M, Sallari R, Delattre O, Zaidi S, Morice S, Surdez D, Danielli SG, Sch\u00e4fer BW, Gryder BE, Wachtel M. PAX3-FOXO1 uses its activation domain to recruit CBP\/P300 and shape RNA Pol2 cluster distribution. Nat Commun. 2023;14:8361. https:\/\/doi.org\/10.1038\/s41467-023-43780-4.","journal-title":"Nat Commun"},{"key":"9984_CR4","doi-asserted-by":"publisher","first-page":"33716","DOI":"10.1074\/jbc.M402839200","volume":"279","author":"K Balasubramanyam","year":"2004","unstructured":"Balasubramanyam K, Altaf M, Varier RA, Swaminathan V, Ravindran A, Sadhale PP, Kundu TK. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem. 2004;279:33716\u201326. https:\/\/doi.org\/10.1074\/jbc.M402839200.","journal-title":"J Biol Chem"},{"key":"9984_CR5","doi-asserted-by":"publisher","first-page":"19134","DOI":"10.1074\/jbc.M301580200","volume":"278","author":"K Balasubramanyam","year":"2003","unstructured":"Balasubramanyam K, Swaminathan V, Ranganathan A, Kundu TK. Small molecule modulators of histone acetyltransferase p300. J Biol Chem. 2003;278:19134\u201340. https:\/\/doi.org\/10.1074\/jbc.M301580200.","journal-title":"J Biol Chem"},{"key":"9984_CR6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/384641a0","volume":"384","author":"AJ Bannister","year":"1996","unstructured":"Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature. 1996;384:641\u20133. https:\/\/doi.org\/10.1038\/384641a0.","journal-title":"Nature"},{"key":"9984_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21:181\u2013200. https:\/\/doi.org\/10.1038\/s41573-021-00371-6.","journal-title":"Nat Rev Drug Discov"},{"key":"9984_CR8","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1093\/nar\/29.21.4462","volume":"29","author":"L Bordoli","year":"2001","unstructured":"Bordoli L, H\u00fcsser S, L\u00fcthi U, Netsch M, Osmani H, Eckner R. Functional analysis of the p300 acetyltransferase domain: the PHD finger of p300 but not of CBP is dispensable for enzymatic activity. Nucleic Acids Res. 2001;29:4462\u201371. https:\/\/doi.org\/10.1093\/nar\/29.21.4462.","journal-title":"Nucleic Acids Res"},{"key":"9984_CR9","doi-asserted-by":"publisher","unstructured":"Bosnakovski D, da Silva MT, Sunny ST, Ener ET, Toso EA, Yuan C, Cui Z, Walters MA, Jadhav A, Kyba M. A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression, and cell death. Sci Adv. 2019;5:eaaw7781. https:\/\/doi.org\/10.1126\/sciadv.aaw7781","DOI":"10.1126\/sciadv.aaw7781"},{"key":"9984_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41389-021-00357-4","volume":"10","author":"D Bosnakovski","year":"2021","unstructured":"Bosnakovski D, Ener ET, Cooper MS, Gearhart MD, Knights KA, Xu NC, Palumbo CA, Toso EA, Marsh GP, Maple HJ, Kyba M. Inactivation of the CIC-DUX4 oncogene through P300\/CBP inhibition, a therapeutic approach for CIC-DUX4 sarcoma. Oncogenesis. 2021;10:68. https:\/\/doi.org\/10.1038\/s41389-021-00357-4.","journal-title":"Oncogenesis"},{"key":"9984_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.chembiol.2010.03.006","volume":"17","author":"EM Bowers","year":"2010","unstructured":"Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert MA, Crump NT, Hazzalin CA, Liszczak G, Yuan H, Larocca C, Saldanha SA, Abagyan R, Sun Y, Meyers DJ, Marmorstein R, Mahadevan LC, Alani RM, Cole PA. Virtual ligand screening of the p300\/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol. 2010;17:471\u201382. https:\/\/doi.org\/10.1016\/j.chembiol.2010.03.006.","journal-title":"Chem Biol"},{"key":"9984_CR12","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/0008-5472.Can-20-1323","volume":"81","author":"LY Cai","year":"2021","unstructured":"Cai LY, Chen SJ, Xiao SH, Sun QJ, Ding CH, Zheng BN, Zhu XY, Liu SQ, Yang F, Yang YX, Zhou B, Luo C, Zhang X, Xie WF. Targeting p300\/CBP attenuates hepatocellular carcinoma progression through epigenetic regulation of metabolism. Cancer Res. 2021;81:860\u201372. https:\/\/doi.org\/10.1158\/0008-5472.Can-20-1323.","journal-title":"Cancer Res"},{"key":"9984_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11523-023-00949-7","volume":"18","author":"M Caligiuri","year":"2023","unstructured":"Caligiuri M, Williams GL, Castro J, Battalagine L, Wilker E, Yao L, Schiller S, Toms A, Li P, Pardo E, Graves B, Azofeifa J, Chicas A, Herbertz T, Lai M, Basken J, Wood KW, Xu Q, Guichard SM. FT-6876, a potent and selective inhibitor of CBP\/p300, is active in preclinical models of androgen receptor-positive breast cancer. Target Oncol. 2023;18:269\u201385. https:\/\/doi.org\/10.1007\/s11523-023-00949-7.","journal-title":"Target Oncol"},{"key":"9984_CR14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.devcel.2019.05.037","volume":"49","author":"SH Chan","year":"2019","unstructured":"Chan SH, Tang Y, Miao L, Darwich-Codore H, Vejnar CE, Beaudoin JD, Musaev D, Fernandez JP, Benitez MDJ, Bazzini AA, Moreno-Mateos MA, Giraldez AJ. Brd4 and P300 confer transcriptional competency during zygotic genome activation. Dev Cell. 2019;49:867\u201381.e8. https:\/\/doi.org\/10.1016\/j.devcel.2019.05.037.","journal-title":"Dev Cell"},{"key":"9984_CR15","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1021\/acs.jmedchem.3c01468","volume":"67","author":"Q Chang","year":"2024","unstructured":"Chang Q, Li J, Deng Y, Zhou R, Wang B, Wang Y, Zhang M, Huang X, Li Y. Discovery of novel PROTAC degraders of p300\/CBP as potential therapeutics for hepatocellular carcinoma. J Med Chem. 2024;67:2466\u201386. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01468.","journal-title":"J Med Chem"},{"key":"9984_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","volume":"24","author":"B Chapuy","year":"2013","unstructured":"Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, Reichert E, Kung AL, Rodig SJ, Young RA, Shipp MA, Bradner JE. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013;24:777\u201390. https:\/\/doi.org\/10.1016\/j.ccr.2013.11.003.","journal-title":"Cancer Cell"},{"key":"9984_CR17","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1038\/s41467-018-05373-4","volume":"9","author":"X Chen","year":"2018","unstructured":"Chen X, Zhang M, Gan H, Wang H, Lee JH, Fang D, Kitange GJ, He L, Hu Z, Parney IF, Meyer FB, Giannini C, Sarkaria JN, Zhang Z. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun. 2018;9:2949. https:\/\/doi.org\/10.1038\/s41467-018-05373-4.","journal-title":"Nat Commun"},{"issue":"Suppl 5","key":"9984_CR18","doi-asserted-by":"publisher","first-page":"S617","DOI":"10.1016\/j.annonc.2021.08.1082","volume":"32","author":"S Crabb","year":"2021","unstructured":"Crabb S, Plummer R, Greystoke A, Carter L, Pacey S, Walter H, Coyle VM, Knurowski T, Clegg K, Ashby F, Pegg N, West W, Brooks N, Hughes A, de Bono J. A phase I\/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of p300\/CBP, as monotherapy in patients with selected molecular alterations. Ann Oncol. 2021;32(Suppl 5):S617. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1082.","journal-title":"Ann Oncol"},{"key":"9984_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-019-1517-4","volume":"573","author":"P Cramer","year":"2019","unstructured":"Cramer P. Organization and regulation of gene transcription. Nature. 2019;573:45\u201354. https:\/\/doi.org\/10.1038\/s41586-019-1517-4.","journal-title":"Nature"},{"key":"9984_CR20","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1021\/acschembio.3c00293","volume":"18","author":"MC Crawford","year":"2023","unstructured":"Crawford MC, Tripu DR, Barritt SA, Jing Y, Gallimore D, Kales SC, Bhanu NV, Xiong Y, Fang Y, Butler KAT, LeClair CA, Coussens NP, Simeonov A, Garcia BA, Dibble CC, Meier JL. Comparative analysis of drug-like EP300\/CREBBP acetyltransferase inhibitors. ACS Chem Biol. 2023;18:2249\u201358. https:\/\/doi.org\/10.1021\/acschembio.3c00293.","journal-title":"ACS Chem Biol"},{"key":"9984_CR21","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1038\/s41467-022-32472-0","volume":"13","author":"H Cui","year":"2022","unstructured":"Cui H, Yi H, Bao H, Tan Y, Tian C, Shi X, Gan D, Zhang B, Liang W, Chen R, Zhu Q, Fang L, Gao X, Huang H, Tian R, Sperling SR, Hu Y, Chen W. The SWI\/SNF chromatin remodeling factor DPF3 regulates metastasis of ccRCC by modulating TGF-\u03b2 signaling. Nat Commun. 2022;13:4680. https:\/\/doi.org\/10.1038\/s41467-022-32472-0.","journal-title":"Nat Commun"},{"key":"9984_CR22","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1038\/s41467-021-26258-z","volume":"12","author":"J Diesch","year":"2021","unstructured":"Diesch J, Le Pann\u00e9rer MM, Winkler R, Casquero R, Muhar M, van der Garde M, Maher M, Herr\u00e1ez CM, Bech-Serra JJ, Fellner M, Rathert P, Brooks N, Zamora L, Gentilella A, de la Torre C, Zuber J, G\u00f6tze KS, Buschbeck M. Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis. Nat Commun. 2021;12:6060. https:\/\/doi.org\/10.1038\/s41467-021-26258-z.","journal-title":"Nat Commun"},{"key":"9984_CR23","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/2159-8290.Cd-21-0385","volume":"12","author":"AD Durbin","year":"2022","unstructured":"Durbin AD, Wang T, Wimalasena VK, Zimmerman MW, Li D, Dharia NV, Mariani L, Shendy NAM, Nance S, Patel AG, Shao Y, Mundada M, Maxham L, Park PMC, Sigua LH, Morita K, Saur Conway A, Robichaud AL, Perez-Atayde AR, Bikowitz MJ, Quinn TR, Wiest OG, Easton J, Schonbrunn E, Bulyk ML, Abraham BJ, Stegmaier K, Look AT, Qi J. EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma. Cancer Discov. 2022;12:730\u201351. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0385.","journal-title":"Cancer Discov"},{"key":"9984_CR24","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd4360","volume":"13","author":"KJ Falkenberg","year":"2014","unstructured":"Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13:673\u201391. https:\/\/doi.org\/10.1038\/nrd4360.","journal-title":"Nat Rev Drug Discov"},{"key":"9984_CR25","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1158\/1541-7786.Mcr-18-0719","volume":"17","author":"V Garcia-Carpizo","year":"2019","unstructured":"Garcia-Carpizo V, Ruiz-Llorente S, Sarmentero J, Gonz\u00e1lez-Corpas A, Barrero MJ. CREBBP\/EP300 bromodomain inhibition affects the proliferation of AR-positive breast cancer cell lines. Mol Cancer Res. 2019;17:720\u201330. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-18-0719.","journal-title":"Mol Cancer Res"},{"key":"9984_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13072-018-0197-x","volume":"11","author":"V Garcia-Carpizo","year":"2018","unstructured":"Garcia-Carpizo V, Ruiz-Llorente S, Sarmentero J, Gra\u00f1a-Castro O, Pisano DG, Barrero MJ. CREBBP\/EP300 bromodomains are critical to sustain the GATA1\/MYC regulatory axis in proliferation. Epigenetics Chromatin. 2018;11:30. https:\/\/doi.org\/10.1186\/s13072-018-0197-x.","journal-title":"Epigenetics Chromatin"},{"key":"9984_CR27","doi-asserted-by":"publisher","unstructured":"Geng X, Wang C, Gao X, Chowdhury P, Weiss J, Villegas JA, Saed B, Perera T, Hu Y, Reneau J, Sverdlov M, Wolfe A, Brown N, Harms P, Bailey NG, Inamdar K, Hristov AC, Tejasvi T, Montes J, Barrionuevo C, Taxa L, Casavilca S, de P\u00e1dua Covas Lage JLA, Culler HF, Pereira J, Runge JS, Qin T, Tsoi LC, Hong HS, Zhang L, Lyssiotis CA, Ohe R, Toubai T, Zevallos-Morales A, Murga-Zamalloa C, Wilcox RA. GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms. Blood Cancer J. 2022;12:149. https:\/\/doi.org\/10.1038\/s41408-022-00745-y","DOI":"10.1038\/s41408-022-00745-y"},{"key":"9984_CR28","doi-asserted-by":"publisher","first-page":"13014","DOI":"10.1074\/jbc.M115.708560","volume":"291","author":"S Ghosh","year":"2016","unstructured":"Ghosh S, Taylor A, Chin M, Huang HR, Conery AR, Mertz JA, Salmeron A, Dakle PJ, Mele D, Cote A, Jayaram H, Setser JW, Poy F, Hatzivassiliou G, DeAlmeida-Nagata D, Sandy P, Hatton C, Romero FA, Chiang E, Reimer T, Crawford T, Pardo E, Watson VG, Tsui V, Cochran AG, Zawadzke L, Harmange JC, Audia JE, Bryant BM, Cummings RT, Magnuson SR, Grogan JL, Bellon SF, Albrecht BK, Sims RJ 3rd, Lora JM. Regulatory T cell modulation by CBP\/EP300 bromodomain inhibition. J Biol Chem. 2016;291:13014\u201327. https:\/\/doi.org\/10.1074\/jbc.M115.708560.","journal-title":"J Biol Chem"},{"key":"9984_CR29","doi-asserted-by":"crossref","unstructured":"Giles F, Witcher M, Brown B. NEO2734: A novel potent oral dual BET and P300\/CBP inhibitor. Ann Oncol. 2018;29(suppl 8).","DOI":"10.1093\/annonc\/mdy279.416"},{"key":"9984_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/onc.2015.92","volume":"35","author":"G Giotopoulos","year":"2016","unstructured":"Giotopoulos G, Chan WI, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E, Campbell PJ, G\u00f6ttgens B, Van Deursen JM, Cole PA, Huntly BJ. The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia. Oncogene. 2016;35:279\u201389. https:\/\/doi.org\/10.1038\/onc.2015.92.","journal-title":"Oncogene"},{"key":"9984_CR31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41580-022-00476-9","volume":"23","author":"M Girbig","year":"2022","unstructured":"Girbig M, Misiaszek AD, M\u00fcller CW. Structural insights into nuclear transcription by eukaryotic DNA-dependent RNA polymerases. Nat Rev Mol Cell Biol. 2022;23:603\u201322. https:\/\/doi.org\/10.1038\/s41580-022-00476-9.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9984_CR32","doi-asserted-by":"publisher","first-page":"10768","DOI":"10.1073\/pnas.1501956112","volume":"112","author":"A Hammitzsch","year":"2015","unstructured":"Hammitzsch A, Tallant C, Fedorov O, O\u2019Mahony A, Brennan PE, Hay DA, Martinez FO, Al-Mossawi MH, de Wit J, Vecellio M, Wells C, Wordsworth P, M\u00fcller S, Knapp S, Bowness P. CBP30, a selective CBP\/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci U S A. 2015;112:10768\u201373. https:\/\/doi.org\/10.1073\/pnas.1501956112.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9984_CR33","doi-asserted-by":"publisher","first-page":"9308","DOI":"10.1021\/ja412434f","volume":"136","author":"DA Hay","year":"2014","unstructured":"Hay DA, Fedorov O, Martin S, Singleton DC, Tallant C, Wells C, Picaud S, Philpott M, Monteiro OP, Rogers CM, Conway SJ, Rooney TP, Tumber A, Yapp C, Filippakopoulos P, Bunnage ME, M\u00fcller S, Knapp S, Schofield CJ, Brennan PE. Discovery and optimization of small-molecule ligands for the CBP\/p300 bromodomains. J Am Chem Soc. 2014;136:9308\u201319. https:\/\/doi.org\/10.1021\/ja412434f.","journal-title":"J Am Chem Soc"},{"key":"9984_CR34","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/s41467-021-21860-7","volume":"12","author":"Y He","year":"2021","unstructured":"He Y, Wei T, Ye Z, Orme JJ, Lin D, Sheng H, Fazli L, Jeffrey Karnes R, Jimenez R, Wang L, Wang L, Gleave ME, Wang Y, Shi L, Huang H. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. Nat Commun. 2021;12:1521. https:\/\/doi.org\/10.1038\/s41467-021-21860-7.","journal-title":"Nat Commun"},{"key":"9984_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/nar\/gkad1126","volume":"52","author":"L Helminen","year":"2024","unstructured":"Helminen L, Huttunen J, Tulonen M, Aaltonen N, Niskanen EA, Palvimo JJ, Paakinaho V. Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer. Nucleic Acids Res. 2024;52:625\u201342. https:\/\/doi.org\/10.1093\/nar\/gkad1126.","journal-title":"Nucleic Acids Res"},{"key":"9984_CR36","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","volume":"155","author":"D Hnisz","year":"2013","unstructured":"Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andre V, Sigova AA, Hoke HA, Young RA. Super-enhancers in the control of cell identity and disease. Cell. 2013;155:934\u201347. https:\/\/doi.org\/10.1016\/j.cell.2013.09.053.","journal-title":"Cell"},{"key":"9984_CR37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1128\/mcb.26.2.457-471.2006","volume":"26","author":"JE Hoberg","year":"2006","unstructured":"Hoberg JE, Popko AE, Ramsey CS, Mayo MW. IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA\/p65 by p300. Mol Cell Biol. 2006;26:457\u201371. https:\/\/doi.org\/10.1128\/mcb.26.2.457-471.2006.","journal-title":"Mol Cell Biol"},{"key":"9984_CR38","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.molcel.2021.04.015","volume":"81","author":"SJ Hogg","year":"2021","unstructured":"Hogg SJ, Motorna O, Cluse LA, Johanson TM, Coughlan HD, Raviram R, Myers RM, Costacurta M, Todorovski I, Pijpers L, Bjelosevic S, Williams T, Huskins SN, Kearney CJ, Devlin JR, Fan Z, Jabbari JS, Martin BP, Fareh M, Kelly MJ, Dup\u00e9r\u00e9-Richer D, Sandow JJ, Feran B, Knight D, Khong T, Spencer A, Harrison SJ, Gregory G, Wickramasinghe VO, Webb AI, Taberlay PC, Bromberg KD, Lai A, Papenfuss AT, Smyth GK, Allan RS, Licht JD, Landau DA, Abdel-Wahab O, Shortt J, Vervoort SJ, Johnstone RW. Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300\/CBP inhibition. Mol Cell. 2021;81:2183\u2013200.e13. https:\/\/doi.org\/10.1016\/j.molcel.2021.04.015.","journal-title":"Mol Cell"},{"key":"9984_CR39","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13148-022-01316-5","volume":"14","author":"SJ Hogg","year":"2022","unstructured":"Hogg SJ, Motorna O, Kearney CJ, Derrick EB, House IG, Todorovski I, Kelly MJ, Zethoven M, Bromberg KD, Lai A, Beavis PA, Shortt J, Johnstone RW, Vervoort SJ. Distinct modulation of IFN\u03b3-induced transcription by BET bromodomain and catalytic P300\/CBP inhibition in breast cancer. Clin Epigenetics. 2022;14:96. https:\/\/doi.org\/10.1186\/s13148-022-01316-5.","journal-title":"Clin Epigenetics"},{"key":"9984_CR40","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.cell.2018.08.058","volume":"175","author":"X Huang","year":"2018","unstructured":"Huang X, Yan J, Zhang M, Wang Y, Chen Y, Fu X, Wei R, Zheng XL, Liu Z, Zhang X, Yang H, Hao B, Shen YY, Su Y, Cong X, Huang M, Tan M, Ding J, Geng M. Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors. Cell. 2018;175:186\u201399.e19. https:\/\/doi.org\/10.1016\/j.cell.2018.08.058.","journal-title":"Cell"},{"key":"9984_CR41","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1101\/gad.350736.123","volume":"37","author":"M Hurd","year":"2023","unstructured":"Hurd M, Pino J, Jang K, Allevato MM, Vorontchikhina M, Ichikawa W, Zhao Y, Gates R, Villalpando E, Hamilton MJ, Faiola F, Pan S, Qi Y, Hung YW, Girke T, Ann D, Seewaldt V, Martinez E. MYC acetylated lysine residues drive oncogenic cell transformation and regulate select genetic programs for cell adhesion-independent growth and survival. Genes Dev. 2023;37:865\u201382. https:\/\/doi.org\/10.1101\/gad.350736.123.","journal-title":"Genes Dev"},{"key":"9984_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bbrc.2021.12.078","volume":"590","author":"N Imayoshi","year":"2022","unstructured":"Imayoshi N, Yoshioka M, Tanaka K, Yang SM, Akahane K, Toda Y, Hosogi S, Inukai T, Okada S, Maloney DJ, Nakahata T, Takita J, Kato I, Ashihara E. CN470 is a BET\/CBP\/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia. Biochem Biophys Res Commun. 2022;590:49\u201354. https:\/\/doi.org\/10.1016\/j.bbrc.2021.12.078.","journal-title":"Biochem Biophys Res Commun"},{"key":"9984_CR43","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1038\/s41388-022-02327-5","volume":"41","author":"D Ji","year":"2022","unstructured":"Ji D, Shang G, Wei E, Jia Y, Wang C, Zhang Q, Zeng L. Targeting CDCP1 gene transcription coactivated by BRD4 and CBP\/p300 in castration-resistant prostate cancer. Oncogene. 2022;41:3251\u201362. https:\/\/doi.org\/10.1038\/s41388-022-02327-5.","journal-title":"Oncogene"},{"key":"9984_CR44","doi-asserted-by":"publisher","first-page":"127854","DOI":"10.1016\/j.bmcl.2021.127854","volume":"39","author":"Z Ji","year":"2021","unstructured":"Ji Z, Clark RF, Bhat V, Matthew Hansen T, Lasko LM, Bromberg KD, Manaves V, Algire M, Martin R, Qiu W, Torrent M, Jakob CG, Liu H, Cole PA, Marmorstein R, Kesicki EA, Lai A, Michaelides MR. Discovery of spirohydantoins as selective, orally bioavailable inhibitors of p300\/CBP histone acetyltransferases. Bioorg Med Chem Lett. 2021;39. https:\/\/doi.org\/10.1016\/j.bmcl.2021.127854.","journal-title":"Bioorg Med Chem Lett"},{"key":"9984_CR45","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.1158\/0008-5472.Can-17-0314","volume":"77","author":"L Jin","year":"2017","unstructured":"Jin L, Garcia J, Chan E, de la Cruz C, Segal E, Merchant M, Kharbanda S, Raisner R, Haverty PM, Modrusan Z, Ly J, Choo E, Kaufman S, Beresini MH, Romero FA, Magnuson S, Gascoigne KE. Therapeutic targeting of the CBP\/p300 bromodomain blocks the growth of castration-resistant prostate cancer. Cancer Res. 2017;77:5564\u201375. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-0314.","journal-title":"Cancer Res"},{"key":"9984_CR46","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nrg.2016.93","volume":"17","author":"PA Jones","year":"2016","unstructured":"Jones PA, Issa JP, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17:630\u201341. https:\/\/doi.org\/10.1038\/nrg.2016.93.","journal-title":"Nat Rev Genet"},{"key":"9984_CR47","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1021\/acs.jmedchem.2c01641","volume":"66","author":"R Kanada","year":"2023","unstructured":"Kanada R, Kagoshima Y, Suzuki T, Nakamura A, Funami H, Watanabe J, Asano M, Takahashi M, Ubukata O, Suzuki K, Aikawa T, Sato K, Goto M, Setsu G, Ito K, Kihara K, Kuroha M, Kohno T, Ogiwara H, Isoyama T, Tominaga Y, Higuchi S, Naito H. Discovery of DS-9300: A highly potent, selective, and once-daily oral EP300\/CBP histone acetyltransferase inhibitor. J Med Chem. 2023;66:695\u2013715. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01641.","journal-title":"J Med Chem"},{"key":"9984_CR48","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1074\/mcp.M116.064451","volume":"16","author":"BR Kim","year":"2017","unstructured":"Kim BR, Coyaud E, Laurent EMN, St-Germain J, Van de Laar E, Tsao MS, Raught B, Moghal N. Identification of the SOX2 interactome by bioid reveals EP300 as a mediator of SOX2-dependent squamous differentiation and lung squamous cell carcinoma growth. Mol Cell Proteomics. 2017;16:1864\u201388. https:\/\/doi.org\/10.1074\/mcp.M116.064451.","journal-title":"Mol Cell Proteomics"},{"key":"9984_CR49","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.celrep.2016.02.045","volume":"14","author":"GJ Kitange","year":"2016","unstructured":"Kitange GJ, Mladek AC, Schroeder MA, Pokorny JC, Carlson BL, Zhang Y, Nair AA, Lee JH, Yan H, Decker PA, Zhang Z, Sarkaria JN. Retinoblastoma binding protein 4 modulates temozolomide sensitivity in glioblastoma by regulating dna repair proteins. Cell Rep. 2016;14:2587\u201398. https:\/\/doi.org\/10.1016\/j.celrep.2016.02.045.","journal-title":"Cell Rep"},{"key":"9984_CR50","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nature24028","volume":"550","author":"LM Lasko","year":"2017","unstructured":"Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, Hansen TM, Risi RM, Frey R, Manaves V, Shaw B, Algire M, Hessler P, Lam LT, Uziel T, Faivre E, Ferguson D, Buchanan FG, Martin RL, Torrent M, Chiang GG, Karukurichi K, Langston JW, Weinert BT, Choudhary C, de Vries P, Van Drie JH, McElligott D, Kesicki E, Marmorstein R, Sun C, Cole PA, Rosenberg SH, Michaelides MR, Lai A, Bromberg KD. Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours. Nature. 2017;550:128\u201332. https:\/\/doi.org\/10.1038\/nature24028.","journal-title":"Nature"},{"key":"9984_CR51","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/s1097-2765(00)80452-9","volume":"5","author":"OD Lau","year":"2000","unstructured":"Lau OD, Kundu TK, Soccio RE, Ait-Si-Ali S, Khalil EM, Vassilev A, Wolffe AP, Nakatani Y, Roeder RG, Cole PA. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell. 2000;5:589\u201395. https:\/\/doi.org\/10.1016\/s1097-2765(00)80452-9.","journal-title":"Mol Cell"},{"key":"9984_CR52","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Loven","year":"2013","unstructured":"Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153:320\u201334. https:\/\/doi.org\/10.1016\/j.cell.2013.03.036.","journal-title":"Cell"},{"key":"9984_CR53","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/neuonc\/noac051","volume":"24","author":"AC Mladek","year":"2022","unstructured":"Mladek AC, Yan H, Tian S, Decker PA, Burgenske DM, Bakken K, Hu Z, He L, Connors MA, Carlson BL, Wilson J, Bommi-Reddy A, Conery A, Eckel-Passow JE, Sarkaria JN, Kitange GJ. RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma. Neuro Oncol. 2022;24:1261\u201372. https:\/\/doi.org\/10.1093\/neuonc\/noac051.","journal-title":"Neuro Oncol"},{"key":"9984_CR54","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1158\/1535-7163.Mct-20-0087","volume":"19","author":"CD Morrison-Smith","year":"2020","unstructured":"Morrison-Smith CD, Knox TM, Filic I, Soroko KM, Eschle BK, Wilkens MK, Gokhale PC, Giles F, Griffin A, Brown B, Shapiro GI, Zucconi BE, Cole PA, Lemieux ME, French CA. Combined targeting of the BRD4-NUT-p300 Axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734. Mol Cancer Ther. 2020;19:1406\u201314. https:\/\/doi.org\/10.1158\/1535-7163.Mct-20-0087.","journal-title":"Mol Cancer Ther"},{"key":"9984_CR55","doi-asserted-by":"publisher","first-page":"e1001647","DOI":"10.1371\/journal.pbio.1001647","volume":"11","author":"SP Mukherjee","year":"2013","unstructured":"Mukherjee SP, Behar M, Birnbaum HA, Hoffmann A, Wright PE, Ghosh G. Analysis of the RelA:CBP\/p300 interaction reveals its involvement in NF-\u03baB-driven transcription. PLoS Biol. 2013;11. https:\/\/doi.org\/10.1371\/journal.pbio.1001647.","journal-title":"PLoS Biol"},{"key":"9984_CR56","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.molcel.2021.03.008","volume":"81","author":"T Narita","year":"2021","unstructured":"Narita T, Ito S, Higashijima Y, Chu WK, Neumann K, Walter J, Satpathy S, Liebner T, Hamilton WB, Maskey E, Prus G, Shibata M, Iesmantavicius V, Brickman JM, Anastassiadis K, Koseki H, Choudhary C. Enhancers are activated by p300\/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release. Mol Cell. 2021;81:2166\u201382.e6. https:\/\/doi.org\/10.1016\/j.molcel.2021.03.008.","journal-title":"Mol Cell"},{"key":"9984_CR57","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.ccell.2023.11.001","volume":"41","author":"L Nicosia","year":"2023","unstructured":"Nicosia L, Spencer GJ, Brooks N, Amaral FMR, Basma NJ, Chadwick JA, Revell B, Wingelhofer B, Maiques-Diaz A, Sinclair O, Camera F, Ciceri F, Wiseman DH, Pegg N, West W, Knurowski T, Frese K, Clegg K, Campbell VL, Cavet J, Copland M, Searle E, Somervaille TCP. Therapeutic targeting of EP300\/CBP by bromodomain inhibition in hematologic malignancies. Cancer Cell. 2023;41:2136\u201353.e13. https:\/\/doi.org\/10.1016\/j.ccell.2023.11.001.","journal-title":"Cancer Cell"},{"key":"9984_CR58","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1158\/2159-8290.Cd-15-0754","volume":"6","author":"H Ogiwara","year":"2016","unstructured":"Ogiwara H, Sasaki M, Mitachi T, Oike T, Higuchi S, Tominaga Y, Kohno T. Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression. Cancer Discov. 2016;6:430\u201345. https:\/\/doi.org\/10.1158\/2159-8290.Cd-15-0754.","journal-title":"Cancer Discov"},{"key":"9984_CR59","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/s0092-8674(00)82001-2","volume":"87","author":"VV Ogryzko","year":"1996","unstructured":"Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 1996;87:953\u20139. https:\/\/doi.org\/10.1016\/s0092-8674(00)82001-2.","journal-title":"Cell"},{"key":"9984_CR60","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.radonc.2014.03.015","volume":"111","author":"T Oike","year":"2014","unstructured":"Oike T, Komachi M, Ogiwara H, Amornwichet N, Saitoh Y, Torikai K, Kubo N, Nakano T, Kohno T. C646, a selective small molecule inhibitor of histone acetyltransferase p300, radiosensitizes lung cancer cells by enhancing mitotic catastrophe. Radiother Oncol. 2014;111:222\u20137. https:\/\/doi.org\/10.1016\/j.radonc.2014.03.015.","journal-title":"Radiother Oncol"},{"key":"9984_CR61","doi-asserted-by":"publisher","first-page":"10078","DOI":"10.1038\/s41598-021-89530-8","volume":"11","author":"H Ono","year":"2021","unstructured":"Ono H, Kato T, Murase Y, Nakamura Y, Ishikawa Y, Watanabe S, Akahoshi K, Ogura T, Ogawa K, Ban D, Kudo A, Akiyama Y, Tanaka S, Ito H, Tanabe M. C646 inhibits G2\/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer. Sci Rep. 2021;11:10078. https:\/\/doi.org\/10.1038\/s41598-021-89530-8.","journal-title":"Sci Rep"},{"key":"9984_CR62","doi-asserted-by":"publisher","first-page":"107642","DOI":"10.1016\/j.jbc.2024.107642","volume":"300","author":"BD Ormsbee Golden","year":"2024","unstructured":"Ormsbee Golden BD, Gonzalez DV, Yochum GS, Coulter DW, Rizzino A. SOX2 represses c-MYC transcription by altering the co-activator landscape of the c-MYC super-enhancer and promoter regions. J Biol Chem. 2024;300. https:\/\/doi.org\/10.1016\/j.jbc.2024.107642.","journal-title":"J Biol Chem"},{"key":"9984_CR63","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1182\/bloodadvances.2022008787","volume":"7","author":"F Pan","year":"2023","unstructured":"Pan F, Iwasaki M, Wu W, Jiang Y, Yang X, Zhu L, Zhao Z, Cleary ML. Enhancer remodeling drives MLL oncogene-dependent transcriptional dysregulation in leukemia stem cells. Blood Adv. 2023;7:2504\u201319. https:\/\/doi.org\/10.1182\/bloodadvances.2022008787.","journal-title":"Blood Adv"},{"key":"9984_CR64","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1093\/nar\/gkq244","volume":"38","author":"D Pasini","year":"2010","unstructured":"Pasini D, Malatesta M, Jung HR, Walfridsson J, Willer A, Olsson L, Skotte J, Wutz A, Porse B, Jensen ON, Helin K. Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic Acids Res. 2010;38:4958\u201369. https:\/\/doi.org\/10.1093\/nar\/gkq244.","journal-title":"Nucleic Acids Res"},{"key":"9984_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.12.004","volume":"129","author":"D Pechalrieu","year":"2017","unstructured":"Pechalrieu D, Etievant C, Arimondo PB. DNA methyltransferase inhibitors in cancer: From pharmacology to translational studies. Biochem Pharmacol. 2017;129:1\u201313. https:\/\/doi.org\/10.1016\/j.bcp.2016.12.004.","journal-title":"Biochem Pharmacol"},{"key":"9984_CR66","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nrg3458","volume":"14","author":"LA Pennacchio","year":"2013","unstructured":"Pennacchio LA, Bickmore W, Dean A, Nobrega MA, Bejerano G. Enhancers: five essential questions. Nat Rev Genet. 2013;14:288\u201395. https:\/\/doi.org\/10.1038\/nrg3458.","journal-title":"Nat Rev Genet"},{"key":"9984_CR67","doi-asserted-by":"publisher","first-page":"5106","DOI":"10.1158\/0008-5472.Can-15-0236","volume":"75","author":"S Picaud","year":"2015","unstructured":"Picaud S, Fedorov O, Thanasopoulou A, Leonards K, Jones K, Meier J, Olzscha H, Monteiro O, Martin S, Philpott M, Tumber A, Filippakopoulos P, Yapp C, Wells C, Che KH, Bannister A, Robson S, Kumar U, Parr N, Lee K, Lugo D, Jeffrey P, Taylor S, Vecellio ML, Bountra C, Brennan PE, O\u2019Mahony A, Velichko S, M\u00fcller S, Hay D, Daniels DL, Urh M, La Thangue NB, Kouzarides T, Prinjha R, Schwaller J, Knapp S. Generation of a Selective Small Molecule Inhibitor of the CBP\/p300 Bromodomain for Leukemia Therapy. Cancer Res. 2015;75:5106\u201319. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-0236.","journal-title":"Cancer Res"},{"key":"9984_CR68","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1101\/gr.209163.116","volume":"27","author":"M Qian","year":"2017","unstructured":"Qian M, Zhang H, Kham SK, Liu S, Jiang C, Zhao X, Lu Y, Goodings C, Lin TN, Zhang R, Moriyama T, Yin Z, Li Z, Quah TC, Ariffin H, Tan AM, Shen S, Bhojwani D, Hu S, Chen S, Zheng H, Pui CH, Yeoh AE, Yang JJ. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP. Genome Res. 2017;27:185\u201395. https:\/\/doi.org\/10.1101\/gr.209163.116.","journal-title":"Genome Res"},{"key":"9984_CR69","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.celrep.2018.07.041","volume":"24","author":"R Raisner","year":"2018","unstructured":"Raisner R, Kharbanda S, Jin L, Jeng E, Chan E, Merchant M, Haverty PM, Bainer R, Cheung T, Arnott D, Flynn EM, Romero FA, Magnuson S, Gascoigne KE. Enhancer Activity Requires CBP\/P300 Bromodomain-Dependent Histone H3K27 Acetylation. Cell Rep. 2018;24:1722\u20139. https:\/\/doi.org\/10.1016\/j.celrep.2018.07.041.","journal-title":"Cell Rep"},{"key":"9984_CR70","doi-asserted-by":"publisher","unstructured":"Ramos YF, Hestand MS, Verlaan M, Krabbendam E, Ariyurek Y, van Galen M, van Dam H, van Ommen GJ, den Dunnen JT, Zantema A, t Hoen PA. Genome-wide assessment of differential roles for p300 and CBP in transcription regulation. Nucleic Acids Res. 2010;38:5396\u2013408. https:\/\/doi.org\/10.1093\/nar\/gkq184","DOI":"10.1093\/nar\/gkq184"},{"key":"9984_CR71","doi-asserted-by":"publisher","first-page":"9162","DOI":"10.1021\/acs.jmedchem.7b00796","volume":"60","author":"FA Romero","year":"2017","unstructured":"Romero FA, Murray J, Lai KW, Tsui V, Albrecht BK, An L, Beresini MH, de Leon BG, Bronner SM, Chan EW, Chen KX, Chen Z, Choo EF, Clagg K, Clark K, Crawford TD, Cyr P, de Almeida ND, Gascoigne KE, Grogan JL, Hatzivassiliou G, Huang W, Hunsaker TL, Kaufman S, Koenig SG, Li R, Li Y, Liang X, Liao J, Liu W, Ly J, Maher J, Masui C, Merchant M, Ran Y, Taylor AM, Wai J, Wang F, Wei X, Yu D, Zhu BY, Zhu X, Magnuson S. GNE-781, a highly advanced potent and selective bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein, binding protein (CBP). J Med Chem. 2017;60:9162\u201383. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00796.","journal-title":"J Med Chem"},{"key":"9984_CR72","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1074\/jbc.M006896200","volume":"276","author":"Y Sano","year":"2001","unstructured":"Sano Y, Ishii S. Increased affinity of c-Myb for CREB-binding protein (CBP) after CBP-induced acetylation. J Biol Chem. 2001;276:3674\u201382. https:\/\/doi.org\/10.1074\/jbc.M006896200.","journal-title":"J Biol Chem"},{"key":"9984_CR73","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1101\/gad.335679.119","volume":"34","author":"AC Schier","year":"2020","unstructured":"Schier AC, Taatjes DJ. Structure and mechanism of the RNA polymerase II transcription machinery. Genes Dev. 2020;34:465\u201388. https:\/\/doi.org\/10.1101\/gad.335679.119.","journal-title":"Genes Dev"},{"key":"9984_CR74","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1158\/1078-0432.Ccr-21-3344","volume":"28","author":"Q Shi","year":"2022","unstructured":"Shi Q, Liu L, Chen J, Zhang W, Guo W, Wang X, Wang H, Guo S, Yue Q, Ma J, Liu Y, Zhu G, Zhao T, Zhao J, Liu Y, Gao T, Li C. Integrative genomic profiling uncovers therapeutic targets of acral melanoma in asian populations. Clin Cancer Res. 2022;28:2690\u2013703. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3344.","journal-title":"Clin Cancer Res"},{"key":"9984_CR75","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1182\/bloodadvances.2020001879","volume":"4","author":"F Spriano","year":"2020","unstructured":"Spriano F, Gaudio E, Cascione L, Tarantelli C, Melle F, Motta G, Priebe V, Rinaldi A, Golino G, Mensah AA, Aresu L, Zucca E, Pileri S, Witcher M, Brown B, Wahlestedt C, Giles F, Stathis A, Bertoni F. Antitumor activity of the dual BET and CBP\/EP300 inhibitor NEO2734. Blood Adv. 2020;4:4124\u201335. https:\/\/doi.org\/10.1182\/bloodadvances.2020001879.","journal-title":"Blood Adv"},{"key":"9984_CR76","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1158\/1535-7163.Mct-05-0135","volume":"4","author":"L Stimson","year":"2005","unstructured":"Stimson L, Rowlands MG, Newbatt YM, Smith NF, Raynaud FI, Rogers P, Bavetsias V, Gorsuch S, Jarman M, Bannister A, Kouzarides T, McDonald E, Workman P, Aherne GW. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther. 2005;4:1521\u201332. https:\/\/doi.org\/10.1158\/1535-7163.Mct-05-0135.","journal-title":"Mol Cancer Ther"},{"key":"9984_CR77","doi-asserted-by":"publisher","unstructured":"Strachowska M, Gronkowska K, Michlewska S, Robaszkiewicz A. CBP\/p300 Bromodomain inhibitor-I-CBP112 declines transcription of the key abc transporters and sensitizes cancer cells to chemotherapy drugs. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13184614","DOI":"10.3390\/cancers13184614"},{"key":"9984_CR78","doi-asserted-by":"publisher","unstructured":"Tao W, Zhang A, Zhai K, Huang Z, Huang H, Zhou W, Huang Q, Fang X, Prager BC, Wang X, Wu Q, Sloan AE, Ahluwalia MS, Lathia JD, Yu JS, Rich JN, Bao S. SATB2 drives glioblastoma growth by recruiting CBP to promote FOXM1 expression in glioma stem cells. EMBO Mol Med. 2020;12:e12291. https:\/\/doi.org\/10.15252\/emmm.202012291","DOI":"10.15252\/emmm.202012291"},{"key":"9984_CR79","doi-asserted-by":"publisher","first-page":"8178","DOI":"10.1021\/acs.jmedchem.3c00492","volume":"66","author":"JE Thomas 2nd","year":"2023","unstructured":"Thomas JE 2nd, Wang M, Jiang W, Wang M, Wang L, Wen B, Sun D, Wang S. Discovery of exceptionally potent, selective, and efficacious PROTAC degraders of CBP and p300 proteins. J Med Chem. 2023;66:8178\u201399. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00492.","journal-title":"J Med Chem"},{"key":"9984_CR80","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/sj.onc.1203329","volume":"19","author":"A Tomita","year":"2000","unstructured":"Tomita A, Towatari M, Tsuzuki S, Hayakawa F, Kosugi H, Tamai K, Miyazaki T, Kinoshita T, Saito H. c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300. Oncogene. 2000;19:444\u201351. https:\/\/doi.org\/10.1038\/sj.onc.1203329.","journal-title":"Oncogene"},{"key":"9984_CR81","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41416-022-01815-5","volume":"127","author":"U Tontsch-Grunt","year":"2022","unstructured":"Tontsch-Grunt U, Traexler PE, Baum A, Musa H, Marzin K, Wang S, Trapani F, Engelhardt H, Solca F. Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic. Br J Cancer. 2022;127:577\u201386. https:\/\/doi.org\/10.1038\/s41416-022-01815-5.","journal-title":"Br J Cancer"},{"key":"9984_CR82","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1002\/hep.30544","volume":"69","author":"FH Tsang","year":"2019","unstructured":"Tsang FH, Law CT, Tang TC, Cheng CL, Chin DW, Tam WV, Wei L, Wong CC, Ng IO, Wong CM. Aberrant super-enhancer landscape in human hepatocellular carcinoma. Hepatology. 2019;69:2502\u201317. https:\/\/doi.org\/10.1002\/hep.30544.","journal-title":"Hepatology"},{"key":"9984_CR83","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1097\/hs9.0000000000000610","volume":"5","author":"N van Gils","year":"2021","unstructured":"van Gils N, Martia\u00f1ez Canales T, Vermue E, Rutten A, Denkers F, van der Deure T, Ossenkoppele GJ, Giles F, Smit L. The novel oral BET-CBP\/p300 dual inhibitor NEO2734 Is highly effective in eradicating acute myeloid leukemia blasts and stem\/progenitor cells. Hemasphere. 2021;5.https:\/\/doi.org\/10.1097\/hs9.0000000000000610","journal-title":"Hemasphere"},{"key":"9984_CR84","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/sj.embor.embor821","volume":"4","author":"J Vervoorts","year":"2003","unstructured":"Vervoorts J, Luscher-Firzlaff JM, Rottmann S, Lilischkis R, Walsemann G, Dohmann K, Austen M, Luscher B. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep. 2003;4:484\u201390.","journal-title":"EMBO Rep"},{"key":"9984_CR85","doi-asserted-by":"publisher","unstructured":"Waddell A, Mahmud I, Ding H, Huo Z, Liao D. Pharmacological inhibition of CBP\/p300 blocks estrogen receptor alpha (ER\u03b1) function through suppressing enhancer H3K27 acetylation in luminal breast cancer. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13112799","DOI":"10.3390\/cancers13112799"},{"key":"9984_CR86","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1158\/1535-7163.Mct-18-0511","volume":"17","author":"R Wang","year":"2018","unstructured":"Wang R, He Y, Robinson V, Yang Z, Hessler P, Lasko LM, Lu X, Bhathena A, Lai A, Uziel T, Lam LT. Targeting lineage-specific MITF pathway in human melanoma cell lines by A-485, the selective small-molecule Inhibitor of p300\/CBP. Mol Cancer Ther. 2018;17:2543\u201350. https:\/\/doi.org\/10.1158\/1535-7163.Mct-18-0511.","journal-title":"Mol Cancer Ther"},{"key":"9984_CR87","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1038\/s41467-018-06178-1","volume":"9","author":"YC Wang","year":"2018","unstructured":"Wang YC, Wu YS, Hung CY, Wang SA, Young MJ, Hsu TI, Hung JJ. USP24 induces IL-6 in tumor-associated microenvironment by stabilizing p300 and \u03b2-TrCP and promotes cancer malignancy. Nat Commun. 2018;9:3996. https:\/\/doi.org\/10.1038\/s41467-018-06178-1.","journal-title":"Nat Commun"},{"key":"9984_CR88","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41375-022-01774-z","volume":"37","author":"W Wei","year":"2023","unstructured":"Wei W, Song Z, Chiba M, Wu W, Jeong S, Zhang JP, Kadin ME, Nakagawa M, Yang Y. Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and hodgkin lymphoma. Leukemia. 2023;37:396\u2013407. https:\/\/doi.org\/10.1038\/s41375-022-01774-z.","journal-title":"Leukemia"},{"key":"9984_CR89","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.cell.2018.04.033","volume":"174","author":"BT Weinert","year":"2018","unstructured":"Weinert BT, Narita T, Satpathy S, Srinivasan B, Hansen BK, Sch\u00f6lz C, Hamilton WB, Zucconi BE, Wang WW, Liu WR, Brickman JM, Kesicki EA, Lai A, Bromberg KD, Cole PA, Choudhary C. Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP\/p300 Acetylome. Cell. 2018;174:231\u201344.e12. https:\/\/doi.org\/10.1016\/j.cell.2018.04.033.","journal-title":"Cell"},{"key":"9984_CR90","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.Cd-20-0751","volume":"11","author":"J Welti","year":"2021","unstructured":"Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand SN, Pal A, Figueiredo I, Riisnaes R, Gurel B, Rekowski J, Bogdan D, West W, Young B, Raja M, Prosser A, Lane J, Thomson S, Worthington J, Onions S, Shannon J, Paoletta S, Brown R, Smyth D, Harbottle GW, Gil VS, Miranda S, Crespo M, Ferreira A, Pereira R, Tunariu N, Carreira S, Neeb AJ, Ning J, Swain A, Taddei D, Schiewer MJ, Knudsen KE, Pegg N, de Bono JS. Targeting the p300\/CBP Axis in lethal prostate cancer. Cancer Discov. 2021;11:1118\u201337. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-0751.","journal-title":"Cancer Discov"},{"key":"9984_CR91","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1021\/acsmedchemlett.0c00155","volume":"11","author":"JE Wilson","year":"2020","unstructured":"Wilson JE, Patel G, Patel C, Brucelle F, Huhn A, Gardberg AS, Poy F, Cantone N, Bommi-Reddy A, Sims RJ 3rd, Cummings RT, Levell JR. Discovery of CPI-1612: A potent, selective, and orally bioavailable ep300\/cbp histone acetyltransferase inhibitor. ACS Med Chem Lett. 2020;11:1324\u20139. https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00155.","journal-title":"ACS Med Chem Lett"},{"key":"9984_CR92","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1038\/s41467-019-11132-w","volume":"10","author":"M Wong","year":"2019","unstructured":"Wong M, Sun Y, Xi Z, Milazzo G, Poulos RC, Bartenhagen C, Bell JL, Mayoh C, Ho N, Tee AE, Chen X, Li Y, Ciaccio R, Liu PY, Jiang CC, Lan Q, Jayatilleke N, Cheung BB, Haber M, Norris MD, Zhang XD, Marshall GM, Wang JY, Huttelmaier S, Fischer M, Wong JWH, Xu H, Perini G, Dong Q, George RE, Liu T. JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma. Nat Commun. 2019;10:3319. https:\/\/doi.org\/10.1038\/s41467-019-11132-w.","journal-title":"Nat Commun"},{"key":"9984_CR93","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.celrep.2018.10.003","volume":"25","author":"T Wu","year":"2018","unstructured":"Wu T, Kamikawa YF, Donohoe ME. Brd4\u2019s bromodomains mediate histone H3 acetylation and chromatin remodeling in pluripotent cells through P300 and Brg1. Cell Rep. 2018;25:1756\u201371. https:\/\/doi.org\/10.1016\/j.celrep.2018.10.003.","journal-title":"Cell Rep"},{"key":"9984_CR94","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1021\/acs.jmedchem.1c01864","volume":"65","author":"Q Xiang","year":"2022","unstructured":"Xiang Q, Wang C, Wu T, Zhang C, Hu Q, Luo G, Hu J, Zhuang X, Zou L, Shen H, Wu X, Zhang Y, Kong X, Liu J, Xu Y. Design, synthesis, and biological evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP bromodomain inhibitors for the treatment of prostate cancer. J Med Chem. 2022;65:785\u2013810. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01864.","journal-title":"J Med Chem"},{"key":"9984_CR95","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1093\/nar\/gky1306","volume":"47","author":"B Xu","year":"2019","unstructured":"Xu B, Li Q, Chen N, Zhu C, Meng Q, Ayyanathan K, Qian W, Jia H, Wang J, Ni P, Hou Z. The LIM protein Ajuba recruits DBC1 and CBP\/p300 to acetylate ER\u03b1 and enhances ER\u03b1 target gene expression in breast cancer cells. Nucleic Acids Res. 2019;47:2322\u201335. https:\/\/doi.org\/10.1093\/nar\/gky1306.","journal-title":"Nucleic Acids Res"},{"key":"9984_CR96","doi-asserted-by":"publisher","unstructured":"Yan Y, Ma J, Wang D, Lin D, Pang X, Wang S, Zhao Y, Shi L, Xue H, Pan Y, Zhang J, Wahlestedt C, Giles FJ, Chen Y, Gleave ME, Collins CC, Ye D, Wang Y, Huang H. The novel BET-CBP\/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. EMBO Mol Med. 2019;11:e10659. https:\/\/doi.org\/10.15252\/emmm.201910659","DOI":"10.15252\/emmm.201910659"},{"key":"9984_CR97","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1021\/acs.jmedchem.9b01721","volume":"63","author":"Y Yang","year":"2020","unstructured":"Yang Y, Zhang R, Li Z, Mei L, Wan S, Ding H, Chen Z, Xing J, Feng H, Han J, Jiang H, Zheng M, Luo C, Zhou B. Discovery of highly potent, selective, and orally efficacious p300\/CBP histone acetyltransferases inhibitors. J Med Chem. 2020;63:1337\u201360. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01721.","journal-title":"J Med Chem"},{"key":"9984_CR98","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1158\/2159-8290.Cd-17-0375","volume":"7","author":"X Yao","year":"2017","unstructured":"Yao X, Tan J, Lim KJ, Koh J, Ooi WF, Li Z, Huang D, Xing M, Chan YS, Qu JZ, Tay ST, Wijaya G, Lam YN, Hong JH, Lee-Lim AP, Guan P, Ng MSW, He CZ, Lin JS, Nandi T, Qamra A, Xu C, Myint SS, Davies JOJ, Goh JY, Loh G, Tan BC, Rozen SG, Yu Q, Tan IBH, Cheng CWS, Li S, Chang KTE, Tan PH, Silver DL, Lezhava A, Steger G, Hughes JR, Teh BT, Tan P. VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discov. 2017;7:1284\u2013305. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0375.","journal-title":"Cancer Discov"},{"key":"9984_CR99","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.canlet.2011.06.030","volume":"310","author":"C Yokomizo","year":"2011","unstructured":"Yokomizo C, Yamaguchi K, Itoh Y, Nishimura T, Umemura A, Minami M, Yasui K, Mitsuyoshi H, Fujii H, Tochiki N, Nakajima T, Okanoue T, Yoshikawa T. High expression of p300 in HCC predicts shortened overall survival in association with enhanced epithelial mesenchymal transition of HCC cells. Cancer Lett. 2011;310:140\u20137. https:\/\/doi.org\/10.1016\/j.canlet.2011.06.030.","journal-title":"Cancer Lett"},{"key":"9984_CR100","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.str.2008.01.010","volume":"16","author":"L Zeng","year":"2008","unstructured":"Zeng L, Zhang Q, Gerona-Navarro G, Moshkina N, Zhou MM. Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP\/p300. Structure. 2008;16:643\u201352. https:\/\/doi.org\/10.1016\/j.str.2008.01.010.","journal-title":"Structure"},{"key":"9984_CR101","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1038\/s41388-020-1301-9","volume":"39","author":"X Zhang","year":"2020","unstructured":"Zhang X, Zegar T, Lucas A, Morrison-Smith C, Knox T, French CA, Knapp S, M\u00fcller S, Siveke JT. Therapeutic targeting of p300\/CBP HAT domain for the treatment of NUT midline carcinoma. Oncogene. 2020;39:4770\u20139. https:\/\/doi.org\/10.1038\/s41388-020-1301-9.","journal-title":"Oncogene"},{"key":"9984_CR102","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1021\/acs.biochem.9b00160","volume":"58","author":"BE Zucconi","year":"2019","unstructured":"Zucconi BE, Makofske JL, Meyers DJ, Hwang Y, Wu M, Kuroda MI, Cole PA. Combination targeting of the bromodomain and acetyltransferase active site of p300\/CBP. Biochemistry. 2019;58:2133\u201343. https:\/\/doi.org\/10.1021\/acs.biochem.9b00160.","journal-title":"Biochemistry"}],"container-title":["Cell Biology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10565-024-09984-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10565-024-09984-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10565-024-09984-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T22:02:31Z","timestamp":1737151351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10565-024-09984-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9984"],"URL":"https:\/\/doi.org\/10.1007\/s10565-024-09984-0","relation":{},"ISSN":["1573-6822"],"issn-type":[{"value":"1573-6822","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All contributing authors agree to the publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}